RxDoctor Payments Data

Joseph Charles, MD

Psychiatry · New York, NYNPI 1245309624

Payments from drug & device makers

$3,395in general payments, 2019–2025

Across 103 payments — averaging $32.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$990
  • Alkermes, Inc.$617
  • Otsuka America Pharmaceutical, Inc.$549
  • Johnson & Johnson$276
  • Vanda Pharmaceuticals Inc.$268
  • Teva Pharmaceuticals USA, Inc.$174
  • plus $519 from 5 others

What the payments were for

  • Food & beverage$3,25796%
  • Education$1384%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,395 in reported general payments places this provider in the 85th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$6,685
Medicare patients
17
Services billed
60

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl27$41,788
TrintellixVortioxetine Hydrobromide32$14,662
Lurasidone Hcl33$4,778
Buspirone Hcl436$4,453
Trazodone Hcl424$2,066
Mirtazapine239$1,941
Memantine Hcl176$1,706
Risperidone221$1,312
Bupropion XlBupropion Hcl100$1,206
Escitalopram Oxalate361$1,081
Quetiapine Fumarate166$986
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$910
Haloperidol22$696
Aripiprazole65$694
Amitriptyline Hcl58$669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$990$41,78827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →